Wen‐Kai Weng

4.4k total citations · 1 hit paper
79 papers, 2.2k citations indexed

About

Wen‐Kai Weng is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Wen‐Kai Weng has authored 79 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 27 papers in Immunology and 26 papers in Pathology and Forensic Medicine. Recurrent topics in Wen‐Kai Weng's work include Lymphoma Diagnosis and Treatment (24 papers), CAR-T cell therapy research (19 papers) and Hematopoietic Stem Cell Transplantation (18 papers). Wen‐Kai Weng is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), CAR-T cell therapy research (19 papers) and Hematopoietic Stem Cell Transplantation (18 papers). Wen‐Kai Weng collaborates with scholars based in United States, Canada and France. Wen‐Kai Weng's co-authors include Ronald Levy, Robert S. Negrin, Debra K. Czerwinski, Shoshana Levy, John M. Timmerman, Frank J. Hsu, Philip W. Lavori, David B. Miklos, Judith A. Shizuru and Sally Arai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Wen‐Kai Weng

70 papers receiving 2.1k citations

Hit Papers

Two Immunoglobulin G Fragment C Receptor Polymorphisms In... 2003 2026 2010 2018 2003 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
    2003 990 citations Wen‐Kai Weng, Ronald Levy profile →

Peers

Wen‐Kai Weng
DG Maloney United States
Diying Shen China
Isabelle Bence‐Bruckler Canada
C. Varns United States
RA Newman United States
KA Foon United States
Johannes Duell Germany
Wolfram Jung Germany
Tom van Meerten Netherlands
Russell Hardy United States
DG Maloney United States
Wen‐Kai Weng
Citations per year, relative to Wen‐Kai Weng Wen‐Kai Weng (= 1×) peers DG Maloney

Countries citing papers authored by Wen‐Kai Weng

Since Specialization
Citations

This map shows the geographic impact of Wen‐Kai Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen‐Kai Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen‐Kai Weng more than expected).

Fields of papers citing papers by Wen‐Kai Weng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen‐Kai Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen‐Kai Weng. The network helps show where Wen‐Kai Weng may publish in the future.

Co-authorship network of co-authors of Wen‐Kai Weng

This figure shows the co-authorship network connecting the top 25 collaborators of Wen‐Kai Weng. A scholar is included among the top collaborators of Wen‐Kai Weng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen‐Kai Weng. Wen‐Kai Weng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nikiforow, Sarah, Jennifer Whangbo, Ran Reshef, et al.. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances. 8(12). 3001–3012. 8 indexed citations
2.
Nie, Esther H., Yi‐Jiun Su, John H. Baird, et al.. (2024). Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Advances. 8(6). 1474–1486. 6 indexed citations
3.
Spinner, Michael A., R. Alejandro Sica, John Tamaresis, et al.. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 141(22). 2727–2737. 10 indexed citations
4.
5.
Su, Yi‐Jiun, Mark Hamilton, Neha Agarwal, et al.. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. Blood. 142(Supplement 1). 1673–1673. 1 indexed citations
6.
Liang, Emily C., Juliana Craig, Kristen Cunanan, et al.. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. 28(8). 490–495. 5 indexed citations
7.
Liang, Emily C., Lori Muffly, Parveen Shiraz, et al.. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. 27(5). 405.e1–405.e6. 5 indexed citations
8.
Muffly, Lori, Parveen Shiraz, Judith A. Shizuru, et al.. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. 27(7). 590.e1–590.e8. 12 indexed citations
9.
Winge, M.C.G., Kerri E. Rieger, Jinah Kim, et al.. (2021). Nutritional deficiency contributing to refractory erythroderma in hematopoietic cell transplant patients: Distinctive clinical and histopathologic findings. Journal of the American Academy of Dermatology. 87(4). 847–848.
10.
Muffly, Lori, Andrew R. Rezvani, Robert Lowsky, et al.. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. 56(2). 368–375. 7 indexed citations
11.
Wang, Jennifer Y., Silvina Pugliese, Darci J. Phillips, et al.. (2019). Pityriasis rubra pilaris‐like graft‐vs‐host disease following allogeneic stem cell transplant in two patients. SHILAP Revista de lepidopterología. 7(12). 2491–2494. 2 indexed citations
12.
Lewis, Jonathan K., Lawrie Skinner, Michael S. Khodadoust, et al.. (2019). Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. Practical Radiation Oncology. 9(4). 220–225. 6 indexed citations
13.
Sica, R. Alejandro, Michael A. Spinner, John Tamaresis, et al.. (2019). Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood. 134(Supplement_1). 2022–2022. 1 indexed citations
14.
15.
Li, Shufeng, et al.. (2017). Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation. Journal of the American Academy of Dermatology. 77(4). 706–712. 19 indexed citations
16.
Benjamin, Jonathan, Saurabh Chhabra, Holbrook E. Kohrt, et al.. (2014). Total Lymphoid Irradiation–Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation. 20(6). 837–843. 16 indexed citations
17.
Kim, Youn H., Bernice Benoit, Cameron Harrison, et al.. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patients. American Journal of Hematology. 87(4). 354–360. 57 indexed citations
18.
Arai, Sally, Ruby M. Wong, Laura Johnston, et al.. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 16(8). 1145–1154. 9 indexed citations
19.
Weng, Wen‐Kai & Ronald Levy. (2009). Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leukemia & lymphoma. 50(9). 1494–1500. 25 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by DG Maloney Breakdown of academic impact, for papers by Diying Shen Breakdown of academic impact, for papers by Isabelle Bence‐Bruckler Breakdown of academic impact, for papers by C. Varns Breakdown of academic impact, for papers by RA Newman Breakdown of academic impact, for papers by KA Foon Breakdown of academic impact, for papers by Johannes Duell Breakdown of academic impact, for papers by Wolfram Jung Breakdown of academic impact, for papers by Tom van Meerten Breakdown of academic impact, for papers by Russell Hardy
Rankless by CCL
2026